Ijraset Journal For Research in Applied Science and Engineering Technology
Authors: Tribhav Rathod, Gajanand Chame, Yogesh Sawant
DOI Link: https://doi.org/10.22214/ijraset.2025.68412
Certificate: View Certificate
Dual Antiplatelet Therapy (DAPT) is a cornerstone in managing thrombotic cardiovascular conditions, particularly in patients undergoing percutaneous coronary intervention (PCI), those with acute coronary syndrome (ACS), and individuals at risk of cerebrovascular and peripheral arterial events. This review explores the mechanisms of various antiplatelet agents, their clinical indications, and the optimal duration of DAPT across different patient populations. While DAPT effectively reduces ischemic complications, prolonged therapy is associated with an increased risk of bleeding, necessitating a tailored approach based on individual risk assessments. Recent advancements, including novel antiplatelet agents and evolving guidelines, emphasize balancing ischemic protection with bleeding risk. This review provides an in-depth analysis of the latest clinical evidence, emerging therapies, and guideline recommendations for optimizing DAPT in various cardiovascular conditions.
Cardiovascular diseases are a leading cause of death globally, with thrombotic events being key in disease progression. Dual antiplatelet therapy (DAPT) has significantly improved outcomes in conditions like acute coronary syndrome (ACS), ischemic stroke, and peripheral artery disease (PAD) by reducing recurrent thrombotic events. Treatment selection and duration depend on patient-specific factors and the balance between ischemic risk and bleeding.
Aspirin (COX inhibitor): Irreversibly inhibits COX-1, reducing thromboxane A2 and preventing platelet aggregation.
Thienopyridines (clopidogrel, prasugrel, ticagrelor): Block the P2Y12 receptor; prasugrel is the most potent.
Glycoprotein IIb/IIIa inhibitors (e.g., abciximab): IV agents used in ACS.
PAR-1 antagonists (vorapaxar): Inhibit thrombin-induced platelet activation.
PDE inhibitors (dipyridamole, cilostazol): Increase cAMP in platelets, reducing aggregation and causing vasodilation.
ACS (STEMI, NSTEMI, UA): Reduces major adverse cardiovascular events.
Post-PCI: 6–12 months for drug-eluting stents, 1 month for bare-metal stents.
CABG: Recommended for 1 year post-ACS.
Ischemic Stroke/TIA: Short-term DAPT (21–30 days).
PAD: Improves walking distance and reduces limb-related events.
Stent Thrombosis Prevention: Essential after PCI.
ACS:
Standard: 12 months.
Short-term (3–6 months): Considered for high bleeding risk patients.
Studies (e.g., CURE, REDUCE, SMART-CHOICE) support shorter duration in selected patients.
Stable CAD:
Long-term DAPT not routinely beneficial (CHARISMA, THEMIS trials).
THEMIS-PCI showed benefit in patients with prior PCI.
Rivaroxaban + ASA (COMPASS) lowered events but increased bleeding.
Post-PCI with AF:
Triple therapy (aspirin + clopidogrel + anticoagulant) for 1 month.
De-escalation to P2Y12 + OAC preferred beyond 1 month to reduce bleeding.
CABG:
ASA started within 6 hours post-op and continued indefinitely.
DAPT (ASA + clopidogrel/ticagrelor) may improve graft patency.
TAVI:
ASA or clopidogrel monotherapy is safer.
DAPT increases bleeding without added benefit.
PAD:
Monotherapy offers limited benefit in asymptomatic PAD.
DAPT or vorapaxar may reduce limb ischemic events but increase bleeding.
Cilostazol improves claudication symptoms and reduces revascularization rates.
DAPT remains a cornerstone in preventing thrombotic complications in patients with cardiovascular diseases, yet its use requires careful consideration of both ischemic and bleeding risks. While standard therapy durations have been established for conditions such as ACS, PCI, and stroke, recent studies suggest that individualized approaches, guided by patient-specific risk factors, may enhance treatment outcomes. The emergence of novel antiplatelet agents and evolving guideline recommendations highlight the need for continuous re-evaluation of DAPT strategies. Future research should focus on refining risk stratification models and exploring alternative therapies to optimize cardiovascular protection while minimizing adverse events. A patient-centered approach, integrating clinical judgment with the latest evidence, is essential for achieving the best outcomes in antiplatelet therapy.
[1] Krötz F, Sohn HY, Klauss V. Antiplatelet drugs in cardiological practice: established strategies and new developments. Vasc Health Risk Manag. 2008;4(3):637-45. [2] Hashemzadeh M, Furukawa M, Goldsberry S, Movahed MR. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. Exp Clin Cardiol. 2008 Winter;13(4):192-7. [3] Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011 Oct;72(4):619-33. [4] Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, Jeong YH, Fabiszak T, Andruszkiewicz A, Gurbel PA. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014 May;30(5):813-28. [5] Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39-46. [6] Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005 Dec 15;6(4):3-11. [7] Virk HUH, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, Birnbaum Y, Levine GN, Smith SC Jr, Krittanawong C. Dual Antiplatelet Therapy: A Concise Review for Clinicians. Life (Basel). 2023 Jul 18;13(7):1580. doi: 10.3390/life13071580. PMID: 37511955; PMCID: PMC10381391. [8] Misumida N., Abo-Aly M., Kim S.M., Ogunbayo G.O., Abdel-Latif A., Ziada K.M. Efficacy and safety of short-term dual antiplatelet therapy (?6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin. Cardiol. 2018;41:1455–1462. doi: 10.1002/clc.23075. [9] Watanabe H., Morimoto T., Natsuaki M., Yamamoto K., Obayashi Y., Ogita M., Suwa S., Isawa T., Domei T., Yamaji K., et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy with 12 Months of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7:407–417. doi: 10.1001/jamacardio.2021.5244. [10] Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med. 2001;345:494–502. doi: 10.1056/NEJMoa010746. [11] Kuno T., Ueyama H., Takagi H., Fox J., Bangalore S. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: Insights from a Network Meta-Analysis of Randomized Trials. Cardiovasc. Revasc. Med. 2020;28:50–56. doi: 10.1016/j.carrev.2020.07.039. [12] Lee S.Y., Hong M.K., Palmerini T., Kim H.S., Valgimigli M., Feres F., Colombo A., Gilard M., Shin D.H., Kim J.S., et al. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients. JACC Cardiovasc. Interv. 2018;11:435–443. doi: 10.1016/j.jcin.2017.10.015. [13] Misumida N., Abo-Aly M., Kim S.M., Ogunbayo G.O., Abdel-Latif A., Ziada K.M. Efficacy and safety of short-term dual antiplatelet therapy (?6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin. Cardiol. 2018;41:1455–1462. doi: 10.1002/clc.23075. [14] Verdoia M., Suryapranata H., Damen S., Camaro C., Benit E., Barbieri L., Rasoul S., Liew H.B., Polad J., Ahmad W.A.W., et al. Gender differences with short-term vs. 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. J. Thromb. Thrombolysis. 2021;52:797–807. doi: 10.1007/s11239-021-02439-x. [15] Hahn J.Y., Song Y.B., Oh J.H., Chun W.J., Park Y.H., Jang W.J., Im E.S., Jeong J.O., Cho B.R., Oh S.K., et al. Effect of P2Y12 Inhibitor Monotherapy vs. Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321:2428–2437. doi: 10.1001/jama.2019.8146. [16] Amsterdam E.A., Wenger N.K., Brindis R.G., Casey D.E., Ganiats T.G., Holmes D.R., Jaffe A.S., Jneid H., Kelly R.F., Kontos M.C., et al. 2014 AHA/ACC Guideline for the Management of Patients with Non–ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130:e344–e426. doi: 10.1161/CIR.0000000000000134. [17] Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur. Heart J. 2021;42:1289–1367. doi: 10.1093/eurheartj/ehaa575. [18] Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Am. J. Ophthalmol. 2006;142:366. doi: 10.1016/j.ajo.2006.06.024. [19] Steg P.G., Bhatt D.L., Simon T., Fox K., Mehta S.R., Harrington R.A., Held C., Andersson M., Himmelmann A., Ridderstråle W., et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N. Engl. J. Med. 2019;381:1309–1320. doi: 10.1056/NEJMoa1908077. [20] Bhatt D.L., Steg P.G., Mehta S.R., Leiter L.A., Simon T., Fox K., Held C., Andersson M., Himmelmann A., Ridderstråle W., et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): A phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. doi: 10.1016/S0140-6736(19)31887-2. [21] Vranckx P., Valgimigli M., Jüni P., Hamm C., Steg P.G., Heg D., van Es G.A., McFadden E.P., Onuma Y., van Meijeren C., et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs. aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940–949. doi: 10.1016/s0140-6736(18)31858-0. [22] Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O., Diaz R., Alings M., Lonn E.M., Anand S.S., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med. 2017;377:1319–1330. doi: 10.1056/NEJMoa1709118. [23] Neumann F.-J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.-P., Falk V., Head S.J., et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. 2019;40:151–226. doi: 10.15829/1560-4071-2019-8-151-226. [24] Members W.C., Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M., Bittl J.A., Cohen M.G., DiMaio J.M., et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114. doi: 10.1161/CIR.0000000000001038. [25] Lip G.Y.H., Collet J.-P., Haude M., Byrne R., Chung E.H., Fauchier L., Halvorsen S., Lau D., Lopez-Cabanillas N., Lettino M., et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA) EP Eur. 2018;21:192–193. doi: 10.1093/europace/euy174. [26] Saito Y., Nazif T., Baumbach A., Tchétché D., Latib A., Kaple R., Forrest J., Prendergast B., Lansky A. Adjunctive Antithrombotic Therapy for Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2020;5:92. doi: 10.1001/jamacardio.2019.4367. [27] Kuno T., Yokoyama Y., Briasoulis A., Mori M., Iwagami M., Ando T., Takagi H., Bangalore S. Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis. J. Am. Heart Assoc. 2021;10:e019490. doi: 10.1161/JAHA.120.019490. [28] Kobari Y., Inohara T., Saito T., Yoshijima N., Tanaka M., Tsuruta H., Yashima F., Shimizu H., Fukuda K., Naganuma T., et al. Aspirin Versus Clopidogrel as Single Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight from the OCEAN-TAVI Registry. Circ. Cardiovasc. Interv. 2021;14:e010097. doi: 10.1161/CIRCINTERVENTIONS.120.010097. [29] Ambler G.K., Waldron C., Contractor U.B., Hinchliffe R.J., Twine C.P. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br. J. Surg. 2020;107:20–32. doi: 10.1002/bjs.11384. [30] Bonaca M.P., Gutierrez J.A., Creager M.A., Scirica B.M., Olin J., Murphy S.A., Braunwald E., Morrow D.A. Vorapaxar in Patients with Peripheral Artery Disease. Circulation. 2016;133:997–1005. doi: 10.1161/CIRCULATIONAHA.115.019355. [31] Thompson P.D., Zimet R., Forbes W.P., Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 2002;90:1314–1319. doi: 10.1016/S0002-9149(02)02869-2. [32] Balsano F., Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation. 1993;87:1563–1569. doi: 10.1161/01.CIR.87.5.1563. [33] Gerhard-Herman M.D., Gornik H.L., Barrett C., Barshes N.R., Corriere M.A., Drachman D.E., Fleisher L.A., Fowkes F.G.R., Hamburg N., Kinlay S., et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686–e725. doi: 10.1161/CIR.0000000000000470. [34] Aboyans V., Ricco J.B., Bartelink M.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., De Carlo M., Debus S., et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: The European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) Eur. Heart J. 2018;39:763–816. doi: 10.1093/eurheartj/ehx095. [35] Strobl F.F., Brechtel K., Schmehl J., Zeller T., Reiser M.F., Claussen C.D., Tepe G. Twelve-Month Results of a Randomized Trial Comparing Mono with Dual Antiplatelet Therapy in Endovascularly Treated Patients with Peripheral Artery Disease. J. Endovasc. Ther. 2013;20:699–706. doi: 10.1583/13-4275MR.1. [36] Tepe G., Bantleon R., Brechtel K., Schmehl J., Zeller T., Claussen C.D., Strobl F.F. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—The MIRROR study: A randomised and double-blinded clinical trial. Eur. Radiol. 2012;22:1998–2006. doi: 10.1007/s00330-012-2441-2. [37] Markus H.S., Droste D.W., Kaps M., Larrue V., Lees K.R., Siebler M., Ringelstein E.B. Dual Antiplatelet Therapy with Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection. Circulation. 2005;111:2233–2240. doi: 10.1161/01.CIR.0000163561.90680.1C. [38] Paciaroni M., Bogousslavsky J. Antithrombotic Therapy in Carotid Artery Stenosis: An Update. Eur. Neurol. 2015;73:51–56. doi: 10.1159/000367988 [39] Wong K.S.L., Chen C., Fu J., Chang H.M., Suwanwela N.C., Huang Y.N., Han Z., Tan K.S., Ratanakorn D., Chollate P., et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): A randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489–497. doi: 10.1016/S1474-4422(10)70060-0. [40] Naylor R., Rantner B., Ancetti S., de Borst G.J., De Carlo M., Halliday A., Kakkos S.K., Markus H.S., McCabe D.J., Sillesen H., et al. Editor’s Choice–European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur. J. Vasc. Endovasc. Surg. 2023;65:7–111. doi: 10.1016/j.ejvs.2022.04.011. [41] Dalainas I., Nano G., Bianchi P., Stegher S., Malacrida G., Tealdi D.G. Dual Antiplatelet Regime Versus Acetyl-acetic Acid for Carotid Artery Stenting. Cardiovasc. Interv. Radiol. 2006;29:519–521. doi: 10.1007/s00270-005-5288-y. [42] McKevitt F., Randall M., Cleveland T., Gaines P., Tan K., Venables G. The Benefits of Combined Anti-platelet Treatment in Carotid Artery Stenting. Eur. J. Vasc. Endovasc. Surg. 2005;29:522–527. doi: 10.1016/j.ejvs.2005.01.012 [43] Abdu F.A., Mohammed A.-Q., Liu L., Xu Y., Che W. Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA): A Review of the Current Position. Cardiology. 2020;145:543–552. doi: 10.1159/000509100 [44] Bossard M., Gao P., Boden W., Steg G., Tanguay J.F., Joyner C., Granger C.B., Kastrati A., Faxon D., Budaj A., et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021;107:1739–1747. doi: 10.1136/heartjnl-2020-318045 [45] Lindahl B., Baron T., Erlinge D., Hadziosmanovic N., Nordenskjöld A., Gard A., Jernberg T. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Nonobstructive [46] Abdu F.A., Liu L., Mohammed A.-Q., Xu B., Yin G., Xu S., Xu Y., Che W. Effect of Secondary Prevention Medication on the Prognosis in Patients with Myocardial Infarction with Nonobstructive Coronary Artery Disease. J. Cardiovasc. Pharmacol. 2020;76:678–683. doi: 10.1097/FJC.0000000000000918 [47] Kim E.S.H. Spontaneous Coronary-Artery Dissection. N. Engl. J. Med. 2020;383:2358–2370. doi: 10.1056/NEJMra2001524. [48] Saw J., Starovoytov A., Humphries K., Sheth T., So D., Minhas K., Brass N., Lavoie A., Bishop H., Lavi S., et al. Canadian spontaneous coronary artery dissection cohort study: In-hospital and 30-day outcomes. Eur. Heart J. 2019;40:1188–1197. doi: 10.1093/eurheartj/ehz007. [49] Adlam D., Alfonso F., Maas A., Vrints C., Writing Committee European Society of Cardiology, acute cardiovascular care association, SCAD study group: A position paper on spontaneous coronary artery dissection. Eur. Heart J. 2018;39:3353–3368. doi: 10.1093/eurheartj/ehy080 [50] Cerrato E., Giacobbe F., Quadri G., Macaya F., Bianco M., Mori R., Biolè C.A., Boi A., Bettari L., Rolfo C., et al. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry. Eur. Heart J. 2021;42:3161–3171. doi: 10.1093/eurheartj/ehab372 [51] Hayes S.N., Kim E.S., Saw J., Adlam D., Arslanian-Engoren C., Economy K.E., Ganesh S.K., Gulati R., Lindsay M.E., Mieres J.H., et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement from the American Heart Association. Circulation. 2018;137:e523–e557. doi: 10.1161/CIR.0000000000000564. [52] Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 2016;67:2224–34. Doi [53] Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–34. Doi [54] Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention [55] . Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 2018;34:214–33. Do [56] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–367. Doi [57] 2. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60. Doi [58] Guerrero C, Ariza-Sole A, Formiga F, et al. Applicability of the PRECISE-DAPT score in elderly patients with myocardial infarction. J Geriatr Cardiol 2018;15:713–17. doi [59] https://ars.els-cdn.com/content/image/1-s2.0-S0002870321004786-gr1_lrg.jpg [60] Piccolo R, Gargiulo G, Franzone A, et al. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention. Ann Intern Med 2017;167:17–25. Do [61] Song L, Guan C, Yan H, et al. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. Catheter Cardiovasc Interv 2018;91:573–81. Do [62] Yoshikawa Y, Shiomi H, Watanabe H, et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies. Circulation 2018;137:551–62. [63] Zhao XY, Li JX, Tang XF, et al. Evaluation of the patterns of non-adherence to anti-platelet regimens in stented patients bleeding score for predicting the long-term out-of-hospital bleeding risk in Chinese patients after percutaneous coronary intervention. Chin Med J (Engl) 2018;131:1406–11. doi: [64] Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, et al. Myocardial infarction risk after discontinuation of thienopyridine therapy in the randomized DAPT study (Dual Antiplatelet Therapy). Circulation 2017;135:1720–32. doi: [65] Lun R, Dhaliwal S, Zitikyte G, Roy DC, Hutton B, Dowlatshahi D. Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. JAMA Neurol. 2022;79(2):141-148. doi: 10.1001/jamaneurol.2021.4514 [66] Wang Y, Meng X, Wang A, et al. ; CHANCE-2 Investigators . Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520-2530. doi: 10.1056/NEJMoa2111749 [67] Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators . Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6(11):961-969. doi: 10.1016/S1474-4422(07)70250-8 [DO [68] https://www.bing.com/images/search?view=detailV2&insightstoken=bcid_SyicYi5Ewz8IPSawq2n2ncJe9.id.....6E*ccid_KJxiLkTD&form=SBIWPA&iss=SBIUPLOADGET&sbisrc=ImgPicker&idpbck=1&selectedindex=0&id=-728131583&ccid=KJxiLkTD&exph=246&expw=421&vt=2&sim=11 [69] Jones W.S., Mulder H., Wruck L.M., Pencina M.J., Kripalani S., Muñoz D., Crenshaw D.L., Effron M.B., Re R.N., Gupta K., et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N. Engl. J. Med. 2021;384:1981–1990. doi: 10.1056/NEJMoa2102137 [70] Byrne R.A., Colleran R. Aspirin for secondary prevention of cardiovascular disease. Lancet. 2020;395:1462–1463. doi: 10.1016/S0140-6736(20)30799-6. [71] Patrono C., Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 2019;16:675–686. doi: 10.1038/s41569-019-0225-y [72] Pan Y., Meng X., Chen W., Jing J., Lin J., Jiang Y., Johnston S.C., Bath P.M., Dong Q., Xu A.-D., et al. Indobufen versus aspirin in acute ischaemic stroke (INSURE): Rationale and design of a multicentre randomised trial. Stroke Vasc. Neurol. 2022;7:e001480. doi: 10.1136/svn-2021-001480 [73] Bhana N., McClellan K.J. Indobufen. Drugs Aging. 2001;18:369–388. doi: 10.2165/00002512-200118050-00007. [74] Wu H., Xu L., Zhao X., Zhang H., Cheng K., Wang X., Chen M., Li G., Huang J., Lan J., et al. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial. Circulation. 2023;147:212–222. doi: 10.1161/CIRCULATIONAHA.122.062762 [75] Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med. 2001;345:494–502. doi: 10.1056/NEJMoa010746 [76] .Paciaroni M., Ince B., Hu B., Jeng J.-S., Kutluk K., Liu L., Lou M., Parfenov V., Wong K.S.L., Zamani B., et al. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Cardiovasc. Ther. 2019;2019:1607181. doi: 10.1155/2019/1607181. [77] Niitsu Y., Jakubowski J.A., Sugidachi A., Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12 Receptor Antagonist Activity. Semin. Thromb. Hemost. 2005;31:184–194. doi: 10.1055/s-2005-869524. [78] Pradhan A., Tiwari A., Caminiti G., Salimei C., Muscoli S., Sethi R., Perrone M.A. Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. Int. J. Environ. Res. Public Health. 2022;19:8977. doi: 10.3390/ijerph19158977. [79] Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007;357:2001–2015. [80] Thomas C.D., Williams A.K., Lee C.R., [81] L.H. Pharmacogenetics of P2Y12 receptor inhibitors. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2023;43:158–175. doi: 10.1002/phar.2758. [82] Triska J., Maitra N., Deshotels M.R., Haddadin F., Angiolillo D.J., Vilahur G., Jneid H., Atar D., Birnbaum Y. A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc. Drugs Ther. 2022:1–23. doi: 10.1007/s10557-022-07373-5. [83] Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2009;361:1045–1057. doi: 10.1056/NEJMoa0904327. [84] Montalescot G., Van’t Hof A.W., Lapostolle F., Silvain J., Lassen J.F., Bolognese L., Cantor W.J., Cequier Á., Chettibi M., Goodman S.G., et al. Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. N. Engl. J. Med. 2014;371:1016–1027. Doi [85] Schüpke S., Neumann F.J., Menichelli M., Mayer K., Bernlochner I., Wöhrle J., Richardt G., Liebetrau C., Witzenbichler B., Antoniucci D., et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2019;381:1524–1534. doi: 10.1056/NEJMoa1908973. [86] Aytekin A., Ndrepepa G., Neumann F.-J., Menichelli M., Mayer K., Wöhrle J., Bernlochner I., Lahu S., Richardt G., Witzenbichler B., et al. Ticagrelor or Prasugrel in Patients with ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2020;142:2329–2337. doi: 10.1161/CIRCULATIONAHA.120.050244. [87] Belviso N., Aronow H.D., Wyss R., Barbour M., Zhang Y., Wen X., Kogut S. Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2021;41:515–525. doi: 10.1002/phar.2530. [88] Venetsanos D., Träff E., Erlinge D., Hagström E., Nilsson J., Desta L., Lindahl B., Mellbin L., Omerovic E., Szummer K.E., et al. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart. [89] Allahham M., Lerman A., Atar D., Birnbaum Y. Why Not Dipyridamole: A Review of Current Guidelines and Re-evaluation of Utility in the Modern Era. Cardiovasc. Drugs Ther. 2021;36:525–532. Doi [90] Harker L.A., Kadatz R.A. Mechanism of action of dipyridamole. Thromb. Res. Suppl. 1983;29:39–46. doi: 10.1016/0049-3848(83)90356-0. [91] Verro P., Gorelick P.B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis. Stroke. 2008;39:1358–1363. doi: 10.1161/STROKEAHA.107.496281. [92] Berger J.S., Krantz M.J., Kittelson J.M., Hiatt W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials. JAMA. 2009;301:1909–1919. doi: 10.1001/jama.2009.623. [93] Cilostazol: A Review of Basic Mechanisms and Clinical Uses-PubMed. [(accessed on 21 April 2023)]; Available online: [94] Kim S.M., Jung J.M., Kim B.J., Lee J.S., Kwon S.U. Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Stroke. 2019;50:3503–3511. doi: 10.1161/STROKEAHA.119.026655. [95] Matsumoto M. Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study. Atheroscler. Suppl. 2005;6:33–40. doi: 10.1016/j.atherosclerosissup.2005.09.003. [96] Shinohara Y., Katayama Y., Uchiyama S., Yamaguchi T., Handa S., Matsuoka K., Ohashi Y., Tanahashi N., Yamamoto H., Genka C., et al. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–968. doi: 10.1016/S1474-4422(10)70198-8 [97] Reilly M., Mohler E.R., Mohler I.E.R. Cilostazol: Treatment of Intermittent Claudication. Ann. Pharmacother. 2001;35:48–56. doi: 10.1345/aph.19408. [98] Scirica B.M., Bonaca M.P., Braunwald E., De Ferrari G.M., Isaza D., Lewis B.S., Mehrhof F., Merlini P.A., Murphy S.A., Sabatine M.S., et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: A prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380:1317–1324. doi: [99] Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., Fox K.A.A., Lipka L.J., Liu X., Nicolau J.C., et al. Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N. Engl. J. Med. 2012;366:1404–1413. doi: 10.1056/NEJMoa1200933. [100] Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., White H.D., Aylward P.E., Wallentin L., Chen E., et al. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N. Engl. J. Med. 2012;366:20–33. doi: 10.1056/NEJMoa1109719. [101] Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., White H.D., Aylward P.E., Wallentin L., Chen E., et al. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N. Engl. J. Med. 2012;366:20–33. doi: 10.1056/NEJMoa1109719 [102] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation ACC/AHA 2016;134:e123–55. [103] D’Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol 2016;117:1714–23. [104] Choi KH, Song YB, Lee JM, et al. Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an analysis from the SMART-DATE randomized trial. Circ Cardiovasc Interv 2020;13:e008530. [105] Zhao X, Li J, Liu F, et al. The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. Eur Heart J Qual Care Clin Outcomes 2022;8:812–20. [106] Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17. [107] Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;373:1274–5. [108] Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015;65:2211–21. [109] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44–122. [110] Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086–97. [111] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60. [112] Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2016;37:390–9. [113] Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340–8. [114] Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015;65:805–15. [115] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation ACC/AHA [116] Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:197–215. [117] Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392:940–9 [118] Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus Cypher to reduce late loss after stenting (excellent) randomized, multicenter study. Circulation 2012;125:505–13. [119] Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015–26. [120] Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–63. [121] Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086–97. [122] Collet JP, Thiele H, Barbato E, et al. Corrigendum to: 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2021;42:2298. [123] Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340–8 [124] Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510–22. [125] Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:2032–42. [126] Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019;321:2428–37. [127] Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:197–215 [128] Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509–24.
Copyright © 2025 Tribhav Rathod, Gajanand Chame, Yogesh Sawant. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Paper Id : IJRASET68412
Publish Date : 2025-04-06
ISSN : 2321-9653
Publisher Name : IJRASET
DOI Link : Click Here